רווח תפעולי לפני ניכוי פחת: enlivex.com (ENLV)

The prospects of Enlivex Therapeutics (ENLV) depend on the outcomes of immunotherapy trials, while the current liquidity reserve remains stable. The company plans to generate revenue by bringing the drug Allocetra to market to combat sepsis. The absolute cash result of operations allows for daily monitoring of the financial condition, and its current level is 0.00. Simultaneously, Enlivex Therapeutics is implementing energy-saving systems and emission filtration in its laboratories.
Enlivex Therapeutics Ltd. (ENLV) - פילוחי מדדים ודוחות פיננסיים

EBITDA cash flow reflects the daily cash balance after deducting operating expenses, allowing for an assessment of the management efficiency of external GMP contracts and laboratories at Enlivex Therapeutics (ENLV). This indicator measures the difference between demand-driven revenue and outsourcing costs, where a stable trend confirms the predictability of the business model, while volatility signals risks associated with third-party vendor dependency and asset quality.